FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070472912> ?p ?o ?g. }

• W2070472912 endingPage "452" @default.
• W2070472912 startingPage "445" @default.
• W2070472912 abstract "A randomized, double-blind, multicenter study (ETV-047) was conducted to evaluate the dose-response relationship of entecavir and compare its antiviral activity and safety with lamivudine in Japanese patients with chronic hepatitis B (CHB).One hundred thirty-seven nucleoside-naive adult patients with CHB were randomized to once-daily oral doses of entecavir 0.01, 0.1, or 0.5 mg or lamivudine 100 mg for 24 weeks. The primary efficacy end point used to evaluate the dose-response relationship was mean change from baseline in serum hepatitis B virus (HBV) DNA level at week 22, as determined by polymerase chain reaction assay.Entecavir demonstrated a clear dose-response relationship, with mean change from baseline in serum HBV DNA level of -3.11, -4.77, and -5.16 log(10) copies/ml with entecavir 0.01, 0.1, and 0.5 mg, respectively. Entecavir 0.5 mg was superior to lamivudine 100 mg for the mean change in HBV DNA level (-5.16 vs. -4.29 log(10) copies/ml; P = 0.007). The overall incidence of adverse events was comparable between treatment groups. Two patients discontinued treatment because of adverse events (one with liver cirrhosis [entecavir 0.5 mg] and one with grade 4 serum alanine aminotransferase (ALT) elevation, nausea, and malaise [lamivudine 100 mg]). Serum ALT flares were observed in four patients; flares were associated with 2 log(10) reductions or more in HBV DNA level and resolved without dose interruption.Entecavir 0.01-0.5 mg is well tolerated and produces a dose-dependent reduction in viral load in nucleoside-naive Japanese patients with CHB. Compared with lamivudine 100 mg, entecavir 0.1 mg demonstrated noninferiority and entecavir 0.5 mg was superior in this population." @default.
• W2070472912 created "2016-06-24" @default.
• W2070472912 creator A5002059217 @default.
• W2070472912 creator A5014582936 @default.
• W2070472912 creator A5017078328 @default.
• W2070472912 creator A5023396801 @default.
• W2070472912 creator A5023958825 @default.
• W2070472912 creator A5028288918 @default.
• W2070472912 creator A5034244372 @default.
• W2070472912 creator A5035221784 @default.
• W2070472912 creator A5044932403 @default.
• W2070472912 creator A5056305013 @default.
• W2070472912 creator A5059237008 @default.
• W2070472912 creator A5067988074 @default.
• W2070472912 creator A5071769151 @default.
• W2070472912 creator A5084794851 @default.
• W2070472912 creator A5086840982 @default.
• W2070472912 date "2009-05-23" @default.
• W2070472912 modified "2023-10-03" @default.
• W2070472912 title "Antiviral activity, dose–response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial" @default.
• W2070472912 cites W1881193782 @default.
• W2070472912 cites W1970657877 @default.
• W2070472912 cites W1972613143 @default.
• W2070472912 cites W1985577568 @default.
• W2070472912 cites W1985860298 @default.
• W2070472912 cites W2004054613 @default.
• W2070472912 cites W2014279976 @default.
• W2070472912 cites W2042653073 @default.
• W2070472912 cites W2055270948 @default.
• W2070472912 cites W2064209815 @default.
• W2070472912 cites W2069030584 @default.
• W2070472912 cites W2087416757 @default.
• W2070472912 cites W2095541672 @default.
• W2070472912 cites W2123543307 @default.
• W2070472912 cites W2126563189 @default.
• W2070472912 cites W2132022069 @default.
• W2070472912 cites W2142338711 @default.
• W2070472912 cites W2143584498 @default.
• W2070472912 cites W2156015715 @default.
• W2070472912 cites W2337617246 @default.
• W2070472912 cites W2943463865 @default.
• W2070472912 doi "https://doi.org/10.1007/s12072-009-9135-0" @default.
• W2070472912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2748381" @default.
• W2070472912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19669249" @default.
• W2070472912 hasPublicationYear "2009" @default.
• W2070472912 type Work @default.
• W2070472912 sameAs 2070472912 @default.
• W2070472912 citedByCount "20" @default.
• W2070472912 countsByYear W20704729122012 @default.
• W2070472912 countsByYear W20704729122013 @default.
• W2070472912 countsByYear W20704729122014 @default.
• W2070472912 countsByYear W20704729122015 @default.
• W2070472912 countsByYear W20704729122017 @default.
• W2070472912 countsByYear W20704729122018 @default.
• W2070472912 countsByYear W20704729122019 @default.
• W2070472912 countsByYear W20704729122020 @default.
• W2070472912 countsByYear W20704729122021 @default.
• W2070472912 crossrefType "journal-article" @default.
• W2070472912 hasAuthorship W2070472912A5002059217 @default.
• W2070472912 hasAuthorship W2070472912A5014582936 @default.
• W2070472912 hasAuthorship W2070472912A5017078328 @default.
• W2070472912 hasAuthorship W2070472912A5023396801 @default.
• W2070472912 hasAuthorship W2070472912A5023958825 @default.
• W2070472912 hasAuthorship W2070472912A5028288918 @default.
• W2070472912 hasAuthorship W2070472912A5034244372 @default.
• W2070472912 hasAuthorship W2070472912A5035221784 @default.
• W2070472912 hasAuthorship W2070472912A5044932403 @default.
• W2070472912 hasAuthorship W2070472912A5056305013 @default.
• W2070472912 hasAuthorship W2070472912A5059237008 @default.
• W2070472912 hasAuthorship W2070472912A5067988074 @default.
• W2070472912 hasAuthorship W2070472912A5071769151 @default.
• W2070472912 hasAuthorship W2070472912A5084794851 @default.
• W2070472912 hasAuthorship W2070472912A5086840982 @default.
• W2070472912 hasBestOaLocation W20704729122 @default.
• W2070472912 hasConcept C126322002 @default.
• W2070472912 hasConcept C159047783 @default.
• W2070472912 hasConcept C197934379 @default.
• W2070472912 hasConcept C2522874641 @default.
• W2070472912 hasConcept C2776175608 @default.
• W2070472912 hasConcept C2777288759 @default.
• W2070472912 hasConcept C2777382497 @default.
• W2070472912 hasConcept C2777869810 @default.
• W2070472912 hasConcept C2779517838 @default.
• W2070472912 hasConcept C2780593183 @default.
• W2070472912 hasConcept C71924100 @default.
• W2070472912 hasConcept C90924648 @default.
• W2070472912 hasConceptScore W2070472912C126322002 @default.
• W2070472912 hasConceptScore W2070472912C159047783 @default.
• W2070472912 hasConceptScore W2070472912C197934379 @default.
• W2070472912 hasConceptScore W2070472912C2522874641 @default.
• W2070472912 hasConceptScore W2070472912C2776175608 @default.
• W2070472912 hasConceptScore W2070472912C2777288759 @default.
• W2070472912 hasConceptScore W2070472912C2777382497 @default.
• W2070472912 hasConceptScore W2070472912C2777869810 @default.
• W2070472912 hasConceptScore W2070472912C2779517838 @default.
• W2070472912 hasConceptScore W2070472912C2780593183 @default.
• W2070472912 hasConceptScore W2070472912C71924100 @default.
• W2070472912 hasConceptScore W2070472912C90924648 @default.

• next